Plaintiff

Celgene Corp.

49 cases as plaintiff.

Cases
49
Active
0
49 closed
Filed
2007–2025
Top venue
D N J
18 cases
Also appears as a defendant in 24 cases → View as defendant

Company profile

Celgene Corporation (Nasdaq: CELG until 2019) was a biopharmaceutical company headquartered at 86 Morris Avenue, Summit, New Jersey. It was spun off from Celanese in 1986 (some sources cite a 1980 origin) and was acquired by Bristol-Myers Squibb in November 2019 for roughly $74 billion — the largest pharmaceutical acquisition at the time. Celgene now operates as a BMS subsidiary/brand rather than an independent public company; its shares no longer trade. Pre-acquisition, its 2018 revenue was approximately $15.3 billion, with roughly 8,000-plus employees globally.

Products / operations. Celgene discovered, developed, and commercialized therapies for cancer and inflammatory disease. Its principal marketed products were Revlimid (lenalidomide) for multiple myeloma and myelodysplastic syndromes; Pomalyst/Imnovid (pomalidomide) for multiple myeloma; Abraxane (nab-paclitaxel) for several solid tumors; Thalomid (thalidomide); and Otezla (apremilast) for psoriasis/psoriatic arthritis — Otezla was divested to Amgen in 2019 as an antitrust condition of the BMS deal. These brands now sit within BMS's legacy portfolio.

Patent-litigation posture. Celgene is an operating company, not a non-practicing entity, and litigates in both directions. Its 21 plaintiff-side cases are almost entirely Hatch-Waxman/ANDA patent suits against generic filers — Cipla, Dr. Reddy's, Hetero Labs, MSN Laboratories, Apotex, and Hikma — concentrated in the District of New Jersey, its home venue. Its 19 defendant-side cases are predominantly antitrust and pay-for-delay/price-fixing claims brought by health insurers, PBMs, and payers seeking damages related to Revlimid and Thalomid.

Notable cases. In re Revlimid & Thalomid Purchaser Antitrust Litigation (D.N.J., 2019) anchors the defendant-side cluster, alongside suits by Cigna, CenterWell, UnitedHealthcare, Molina Healthcare, Blue Cross Blue Shield, and MSP Recovery Claims. On the plaintiff side, Celgene Corp. v. Cipla and Celgene Corp. v. Dr. Reddy's Laboratories reflect the recurring lenalidomide patent disputes and their Federal Circuit appeals. No cases appear in plaintiff-friendly Eastern District of Texas; the docket is New Jersey- and New York-centric.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Filing activity

2007: 2 cases'07'092010: 1 case'112012: 1 case'132015: 1 case'152016: 1 case2017: 13 cases13'172018: 5 cases2019: 7 cases'192020: 2 cases2021: 2 cases'212022: 1 case'232025: 1 case'25
Cases filed per year with Celgene Corp. as plaintiff.

Celgene Corp. v. Cipla Ltd.

consent judgment; closed
Docket:
2:25-cv-01147
Filed:
2025-02-10
Terminated:
2025-09-17

Hatch-Waxman ANDA litigation concerning Cipla ANDA No. 219718 (1/2/3/4 mg). Consent judgment entered Sept. 11, 2025; case closed Sept. 17, 2025. Patents-in-suit: 8,828,427; 9,993,467; 10,555,939. Injunction until expiration; no damages.

Celgene Corp. v. MSN Laboratories Private Limited et al.

consent judgment
Docket:
2:22-cv-01993
Filed:
2022-04-06
Terminated:
2022-06-15

Hatch-Waxman ANDA litigation. Consent judgment entered June 15, 2022 (Judge Esther Salas): permanent injunction; all claims/counterclaims dismissed with prejudice. Patents-in-suit expressly included 8,828,427 plus '262, '939, '428, '467, '5939.

Celgene Corp. v. Sun Pharmaceutical Industries, Inc.

settled
Docket:
2:21-cv-01734
Court:
D.N.J.
Filed:
2021-02-02
Terminated:
2021-06-21
Patents:9101622

Celgene sued Sun Pharmaceutical Industries and others in a D.N.J. ANDA action involving ANDA No. 211846; the case settled on June 21, 2021, with limited quantities after March 2022 and unlimited from January 31, 2026.

Celgene Corp. v. Aurobindo Pharma Ltd. et al.

settled
Docket:
2:20-cv-00315
Filed:
2020-01-08
Terminated:
2021-07-19
Patents:7855217

Celgene sued Aurobindo entities in D.N.J. (2:20-cv-00315), asserting U.S. 7,855,217 among other patents. The case settled on July 15, 2021, and terminated July 19, 2021 (ANDA No. 213885).

Celgene Corp. v. Mylan Pharmaceuticals Inc. et al.

settled
Docket:
1:20-cv-00003
Filed:
2020-01-03
Terminated:
2021-07-23
Patents:7855217

Celgene sued Mylan Pharmaceuticals, Mylan Inc., and Mylan N.V. in the Northern District of West Virginia (1:20-cv-00003), asserting U.S. 7,855,217 among other patents. The case settled on July 21, 2021, and terminated July 23, 2021 (ANDA No. 213912).

Celgene Corp. v. Hetero Labs Limited

settled/licensed
Docket:
2:19-cv-15449
Court:
D.N.J.
Filed:
2019-07-16
Patents:7189740

Celgene action against Hetero Labs Limited et al.; settled/licensed under later-filer volume allocation.

Celgene Corp. v. Hetero Labs Ltd.

settled
Filed:
2019-07-16
Patents:8404717

Celgene asserted the '717 patent, along with other patents, against Hetero Labs Ltd. et al. The case was settled or otherwise resolved as part of the serial sham-litigation settlements alleged in the antitrust MDL; the exact civil-action number was not confirmed.

Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.

consent judgment
Docket:
2:19-cv-15343; 2:21-cv-02111
Filed:
2019-07-12
Terminated:
2022-01-28

Hatch-Waxman ANDA patent-infringement suit involving pomalidomide (ANDA No. 213234). Patents asserted included U.S. 8,198,262, 8,673,939, 8,735,428, 8,828,427, and U.S. 9,993,467. A consent judgment enjoined Dr. Reddy's from infringing the patents-in-suit until expiration and dismissed all claims, counterclaims, and defenses with prejudice.

Celgene Corp. v. Cipla Ltd.

settled
Docket:
2:19-cv-14731
Court:
D.N.J.
Filed:
2019-07-03

Celgene's consolidated action against Cipla consolidated 2:17-cv-06163 and 2:18-cv-08964. It settled in Dec. 2020; the consolidated Cipla action carried the '357, '219, and '598 patents from 2:18-cv-08964.

Celgene Corp. v. Cipla Limited

settled
Docket:
2:19-cv-14731
Court:
D.N.J.
Filed:
2019-07-03
Terminated:
2020-12-11
Patents:7189740

Celgene action against Cipla; settled Dec 11, 2020, with a volume-limited license and entry in Sept 2022.

Celgene Corp. v. Apotex Inc.

settled
Docket:
2:19-cv-06999
Court:
D.N.J.
Filed:
2019-02-26
Patents:7189740

Celgene action against Apotex; settled around 2021 amid allegations of a reverse-payment/profit-share agreement.

Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.

settled
Docket:
2:18-cv-06378
Court:
D.N.J.
Filed:
2018-04-12
Terminated:
2020-09-17

Celgene sued Dr. Reddy's Laboratories over generic lenalidomide; the asserted patents included the '784 patent along with 6,315,720, 6,561,977, and 8,626,531. The case settled in 2020, with DRL licensed to sell volume-limited generic lenalidomide after March 2022 and unlimited from no earlier than January 31, 2026.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

settled
Docket:
2:17-cv-06842
Filed:
2017-09-06
Terminated:
2019-03-30
Patents:7189740

16-count complaint with the '740 patent among patents-in-suit; motion for judgment on the pleadings on REMS patents denied without prejudice Dec 14, 2018. Later settled March 30, 2019, with Lotus/Alvogen licensed to sell a limited-volume generic after March 2022.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

settled/consent judgment
Docket:
2:17-cv-06842
Filed:
2017-09-06
Terminated:
2019-09-05

Celgene sued Lotus and Alvogen in D.N.J. asserting a portfolio including US 8,626,531. The court bifurcated and stayed claims as to several patents, and a consent judgment/injunction was entered; the case terminated Sept. 5, 2019.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

settled
Docket:
2:17-cv-06842
Court:
D.N.J.
Filed:
2017-09-06
Terminated:
2019-03-29
Patents:9101622

Celgene sued Lotus Pharmaceutical and Alvogen Pine Brook in a D.N.J. ANDA action involving ANDA No. 210480; the case settled with a consent judgment/injunction on March 29, 2019, including a volume-limited licence.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

consent judgment
Docket:
2:17-cv-06842
Filed:
2017-09-06
Terminated:
2019-03-29
Patents:7855217

Celgene sued Lotus Pharmaceutical and Alvogen Pine Brook in D.N.J. (2:17-cv-06842), with U.S. 7,855,217 among the patents-in-suit. A consent judgment was entered on March 29, 2019, after Celgene withdrew an earlier covenant not to sue on '217.

Celgene Corp. v. Cipla Ltd.

settled
Docket:
2:17-cv-06163
Court:
D.N.J.
Filed:
2017-08-15
Terminated:
2020-12-11
Patents:9101622

Celgene sued Cipla in a D.N.J. ANDA action involving ANDA No. 210435; the case was consolidated into 2:19-cv-14731 on June 8, 2020, and settled on December 11, 2020.

Celgene Corp. v. Hetero Labs Ltd. et al.

terminated
Docket:
2:17-cv-03387
Filed:
2017-05-11
Terminated:
2021-08-19
Patents:8828427

Hatch-Waxman ANDA litigation. The '427 was expressly named among the patents-in-suit, but Celgene withdrew its '427 infringement claims. Consolidated/coordinated for claim construction with 17-cv-03159. Case terminated 2021-08-19.

Celgene Corp. v. Dr. Reddy's Laboratories, Inc.

settled
Filed:
2016-10-20
Terminated:
2020-09-17
Patents:7855217

Celgene sued Dr. Reddy's Laboratories in D.N.J. over generic lenalidomide, with U.S. 7,855,217 among the asserted patents. The case settled, and a consent judgment was entered on September 17, 2020, with Dr. Reddy's agreeing not to market generic Revlimid until expiration of the asserted patents. The docket number was not directly confirmed in the narrative.

Celgene Corp. v. Natco Pharma Ltd. et al.

settled
Docket:
2:10-cv-05197
Filed:
2010-10-08
Terminated:
2016-01-05
Patents:8404717

Celgene brought this ANDA patent-infringement suit against Natco, Arrow, and Watson. The '717 patent was added by Fifth Amended Complaint on May 6, 2013, and the case settled on December 22, 2015, with a license to market generic lenalidomide beginning January 31, 2026; the docket terminated January 5, 2016.

Celgene Corp. v. Barr Laboratories, Inc.

dismissed without prejudice
Docket:
2:07-cv-04050
Court:
D.N.J.
Filed:
2007-08-23
Terminated:
2010-05-21
Patents:7230012

Celgene sued Barr Laboratories and others, asserting U.S. Patent 7,230,012 after Barr amended its ANDA to include a paragraph IV certification. The case was consolidated with 07-286, 07-5458, and 08-3357, and all claims/counterclaims were dismissed without prejudice by stipulation filed 2010-05-21.

Celgene Corp. et al. v. Barr Laboratories, Inc.

dismissed
Docket:
2:07-cv-00286
Court:
D.N.J.
Filed:
2007-01-18
Terminated:
2010-05-26

Celgene Corp. and Children's Medical Center Corp. sued Barr Laboratories over thalidomide ANDA; the '784 patent was among the patents-in-suit. The case was dismissed after Barr withdrew its ANDA, with Barr's antitrust counterclaims dismissed with prejudice and patent claims dismissed without prejudice.

Celgene Corp. v. Sandoz Inc.

consent judgment
Docket:
2:25-cv-16878
Terminated:
2025-11-17

Hatch-Waxman ANDA litigation concerning Sandoz ANDA No. 220741. Consent judgment Nov. 17, 2025: permanent injunction barring Sandoz's ANDA product until expiration of patents-in-suit; § 271(e)(1) and Paragraph IV rights expressly preserved.

Celgene Corp. v. Mylan

dismissed
Docket:
2:19-cv-05802
Patents:8828427

Identified in the Cigna complaint as Celgene Corp. v. Mylan; opinion at 2020 WL 12570814 (D.N.J. Sept. 25, 2020) granted Mylan's motion to dismiss for improper venue.

Untitled case

unverified
Docket:
2:17-cv-05314
Court:
D.N.J.
Patents:7189740

Listed on the patent record; caption and outcome unverified.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

consent judgment; dismissed with prejudice
Docket:
2:17-cv-06842
Terminated:
2019-03-29
Patents:5635517

Celgene lenalidomide ANDA suit against Lotus and Alvogen; the '517 patent was expressly named among the patents-in-suit. A consent judgment entered March 29, 2019, included an injunction and dismissal with prejudice, with settlement allowing generic lenalidomide launch after March 2022 under volume limits.